HSV-2 ICP10 Antibody (206): sc-66052

HSV-2 ICP10 Antibody (206) is a mouse monoclonal IgG1 antibody that detects HSV-2 ICP10 protein of HSV-2 origin by immunofluorescence (IF). HSV-2 ICP10 (206) antibody is available as the non-conjugated form. The herpes simplex virus (HSV), known for causing contagious diseases such as cold sores, has a complex structure crucial for function and pathogenicity. HSV-2 ICP10 plays a vital role as the large subunit of the virus′s ribonucleotide reductase, essential for viral replication as HSV-2 ICP10 catalyzes the conversion of ribonucleotides to deoxyribonucleotides, providing necessary building blocks for DNA synthesis. This enzymatic activity allows efficient genome replication within host cells, contributing to acute and latent infections. HSV-2 ICP10 structure includes a serine/threonine protein kinase domain at the amino-terminus and an RR domain at the carboxy-terminus, facilitating enzymatic function and enhancing interaction with host signaling pathways, potentially increasing ras activity and influencing transformation-related signaling. HSV-2 ICP10′s ability to modulate these pathways underscores significance in the viral life cycle and potential as a target for therapeutic interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HSV-2 ICP10 Antibody (206) References:

1. Rapid diagnosis and quantification of herpes simplex virus with a green fluorescent protein reporter system.  |  Kung, SH., et al. 2000. J Virol Methods. 90: 205-12. PMID: 11064120
2. Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK.  |  Gyotoku, T., et al. 2002. Vaccine. 20: 2796-807. PMID: 12034107
3. A cell line that secretes inducibly a reporter protein for monitoring herpes simplex virus infection and drug susceptibility.  |  Wang, YC., et al. 2002. J Med Virol. 68: 599-605. PMID: 12376969
4. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections.  |  Casanova, G., et al. 2002. Cutis. 70: 235-9. PMID: 12403316
5. The HSV-2 protein ICP10PK prevents neuronal apoptosis and loss of function in an in vivo model of neurodegeneration associated with glutamate excitotoxicity.  |  Golembewski, EK., et al. 2007. Exp Neurol. 203: 381-93. PMID: 17046754
6. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.  |  Li, H., et al. 2007. J Gene Med. 9: 161-9. PMID: 17266169
7. An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells.  |  Fu, X., et al. 2007. Gene Ther. 14: 1218-25. PMID: 17538637
8. Cell type-specific induction and inhibition of apoptosis by Herpes Simplex virus type 2 ICP10.  |  Han, JY., et al. 2009. J Virol. 83: 2765-9. PMID: 19116254
9. Intracellular localization and serological identification of a HSV-2 protein in cervical cancer.  |  Costa, S., et al. 1986. Eur J Gynaecol Oncol. 7: 1-12. PMID: 3009194
10. Intracellular internalization and signaling pathways triggered by the large subunit of HSV-2 ribonucleotide reductase (ICP10).  |  Hunter, JC., et al. 1995. Virology. 210: 345-60. PMID: 7618272
11. The transmembrane domain of the large subunit of HSV-2 ribonucleotide reductase (ICP10) is required for protein kinase activity and transformation-related signaling pathways that result in ras activation.  |  Smith, CC., et al. 1994. Virology. 200: 598-612. PMID: 8178446
12. The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2.  |  Peng, T., et al. 1996. Virology. 216: 184-96. PMID: 8614985

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-HSV-2 ICP10 Antibody (206) has 0 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

HSV-2 ICP10 Antibody (206) Specifications

Alternate Product Name: HSV-2 ICP10

Product Clone Name: 206

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: HSV-2 ICP10

Epitope Species: HSV-1/2

Product Reactivity/Detection: ICP10

Species Reactivity/Detection: HSV-2

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: IF

Vialing Information: Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for HSV-2 ICP10 Antibody (206): N/A